The European Medicines Agency (EMA) says it has seen no new evidence that points to a need to amend the current labelling of HRT medicines.
On Monday (10 November), the US Department of Health and Human Services (HHS), led by Robert Kennedy, announced that the US medicines regulator, the FDA, would initiate the removal of ‘black box’ warnings from hormone replacement therapies (HRT). Black box warnings are used to indicate that a medication may present serious risks…
To read the rest of this article, click here.
